Dr. Kaye and Dr. Dhor have assembled top experts to write about facility planning and management in Part I of their two issues devoted to Infection Prevention and Control in Healthcare. Articles in this issue are devoted to: Building a Successful Infection Control Program: Key Components, Processes and Economics; Hand Hygiene Sterilization; High Level Disinfection and Environmental Cleaning; Environement of Care; Infection Control in Alternative Healthcare Settings (Long Term Care and Ambulatory); Antibiotic Stewardship; Outbreak InvestigationsWater Safety in Healthcare/Legionella in the Healthcare Setting; Construction and Renovation; Bloodborne and Body Fluid Exposures - prevention and management of Occupational Health Issues; and Informatics and Statistics in Infection Control. Part II is devoted to clinical management of infections.
Infection Prevention and Control in Healthcare, Part II: Clinical Management of Infections, An Issue of Infectious Disease Clinics of North America, E-Book
Dr. Kaye and Dr. Dhor have assembled top experts to write about clinical management of infections in Part II of their two issues devoted to Infection Prevention and Control in Healthcare. Articles in this issue are devoted to: CLABSI; UTI; Tuberculosis; Ventilator-Assisted Pneumonia; Surgical Site Infection; MRSA; VRE; Gram-Negative Bacilli; Fungal Infections; C. Difficile, and Emerging Infections including Ebola. Infectious Disease physicians and anyone in the hospital setting will find this issue very useful, as state-of-the-art clinical reviews provide clinical management on these common and emerging infections.
There have been major advances in new therapies, diagnostic tools, and strategies for treatment and prevention of fungal infections. Despite these encouraging developments, large numbers of patients are at risk for infectious diseases, and the epidemiology of invasive mycoses continues to emerge. The diagnosis of these infections remains difficult, and treatment outcomes in highly immunosuppressed patients remain poor. Thus, this issue is devoted to state-of-the-art updates on fungal infections by internationally recognized authorities in this field. Some topics covered are Antifungal agents; State-of-the-art culture, identification, and resistance testing of fungal pathogens; Non-culture diagnostics in fungal disease; Contemporary strategies in the prevention and management of fungal infections; Invasive candidiasis; Invasive aspergillosis; Mucormycoses; and Cryptococcosis to name a few.
This comprehensive issue will present the state-of-the-art knowledge on Legionnaire's disease, coming from the country's top experts. Articles are devoted to: History of Legionnaire’s Disease; Microbiology of Legionnaire’s Disease; Epidemiology of Legionnaire’s Disease; Clinical Features of Legionnaire’s Disease; Radiologic Features of Legionnaire’s Disease; Legionella Endocarditis; Legionnaire’s Disease Mimics; Legionnaire’s disease in Compromised Hosts; Legionnaire’s Disease in HIV; Travel-Related Legionnaire’s Disease; Legionnaire’s Outbreaks; Laboratory Diagnosis of Legionnaire’s Disease; and Antimicrobial therapy of Legionnaire’s Disease.
Dr. Schmitt has put together a comprehensive issue devoted to bone and joint infections. Top experts have created state-of-the-art clinical reviews devoted to the following topics: Native septic arthritis; Reactive arthritis; Prevention of infection in orthopedic prosthetic surgery; Infections of the spine; Radiologic approach to musculoskeletal infections; Infections associated with open fractures; Fungal musculoskeletal infections; Mycobacterial musculoskeletal infections; Diagnosis of prosthetic joint infections-cultures, biomarkers, and criteria; Management of Prosthetic Joint Infections; Osteomyelitis In adults; and Osteomyelitis in children. Readers will come away with clinical information that can be immediately applied to caring for patients recovering from orthopedic surgeries.
For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990’s. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or mental illness. This situation has led the U.S. federal government to take a more active lead in addressing antibiotic resistance. Recently, the White House announced an action plan that includes improving surveillance, developing better diagnostic tools, accelerating drug development, and improving global coordination of antibiotic resistance issues. Equally important is the $1.2 billion dollars that has been pledged to fund these efforts. While we await the implementation of new policies, this issue of Infectious Disease Clinics of North America brings together leading authorities in the field of antibiotic resistance who discuss current issues including antibiotic stewardship, the changing role of the microbiology laboratory in determining antibiotic resistance in gram-negative pathogens, the continuing spread of metallo-ß-lactamases, ESBLs and KPCs, antibiotic options for treating resistant gram-negative infections such as colistin and tigecycline, resistance mechanisms and new treatment options for Mycobacterium tuberculosis, emerging resistance mechanisms in aminoglycosides, issues with antibiotic resistance in immunocompromised patients, new ß-lactamase inhibitors in the clinic, and resistance in VRE and Staphylococcus aureus. Additionally, combination therapy for resistant gram-negative infections has been advocated by some authorities and the advantages and disadvantages of this strategy will be reviewed.
This issue of Medical Clinics, guest edited by Drs. Michael P. Pignone and Kirsten Bibbins-Domingo, is devoted to Disease Prevention. Articles in this issue address prevention for various diseases, including: Breast Cancer; Cervical Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer; and Screening for Depression. Lipids, CV Risk Assessment, Blood Pressure, and Aspirin for Primary Prevention will also be addressed.
This issue of Infectious Disease Clinics of North America, Guest Edited by Mary Anne Jackson, MD and Angela Myers, MD, is Part II of a 2-part issue devoted to Pediatric Infectious Diseases. Drs. Jackson and Myers have assembled a group of expert authors to review the following topics: Measles 50 Years After Initiation of MMR Vaccine; Pertussis in the Era of New Strains; Promoting Vaccine Confidence; The Changing Epidemiology of Meningococcal Infection; Prevention of Influenza in Children; Rabies - Rare Human Infection, Common Questions; The Expanded Impact of Human Papillomavirus Vaccine; The Challenge of Global Poliomyelitis Eradication; The Eradication of Pediatric Rotavirus Infection; Approach to Immunization for the Traveling Child; and Status of Pneumococcal Infection in the US in the conjugate vaccine era.
